Click on the link below to see confirmation of Cromos Pharma being an active partner of BMSN's recent news of filing an Investigational New Drug (IND) application with the FDA for the stem cell drug HemaXellerate I™ as per Cromos Pharma CEO Dr. Vladimir Bogin.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.